Alkermes plc, of Dublin, said data from its phase I study of ALKS 8700, a monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis, showed the drug was generally well tolerated and provided MMF exposures comparable to Tecfidera (dimethyl fumarate, Biogen Inc.), with less variability and favorable gastrointestinal (GI) tolerability.